VEGFA and hepatocellular carcinoma: However, given the positive impact of VEGF-related AEs on clinical outcomes, caution should be exercised while reducing the dose or changing the treatment strategy for patients with HCC who experience these AEs while receiving targeted therapy, including these agents.